1. Introduction {#sec1}
===============

Deep Brain Stimulation (DBS) has been established as a superior therapeutic option for advanced Parkinson\'s disease (PD) [@bib1]. Increased body mass index (BMI) after DBS has been repeatedly reported in literature and several theories have been proposed to explain this interesting finding [@bib2]. One possible explanation suggests that patients gain weight after DBS secondary to a reduction in their metabolic rate after resolution of tremor and/or dyskinesia \[[@bib3], [@bib4]\]. Others suggested that DBS might have a direct stimulation effect on appetite centers [@bib5]. However, the differential effect of PD clinical subtypes on BMI changes after DBS is not clear. Do patients with tremor-predominant PD gain more weight after DBS compared to those with hypokinetic-rigid disease as a factor of tremor resolution? Can DBS affect patients\' standing height as a factor of improved axial rigidity and posture? Is the effect on height different in hypokinetic-rigid patients compared to those with tremor-predominant disease? How does the effect on height influence BMI changes after DBS? We sought to answer those questions and explore their clinical implications on PD patients undergoing DBS.

2. Methods {#sec2}
==========

We chart-reviewed PD patients who underwent DBS at the Cleveland Clinic between 2006 and 2011 with complete data. Weight and height data were obtained at the latest preoperative evaluation, at 1-year post surgery, and at the latest available follow-up (LAF). Weight and height for all patients were measured by the intake nurse at our movement disorders center using the same scales. Patients were weighed in the on-state while fully dressed and were asked to stand as erect as possible during height measurement per height measuring standards. We classified patients into tremor-predominant PD versus hypokinetic-rigid PD based on the predominant symptoms and the tremor versus bradykinesia/rigidity subscores on the unified Parkinson disease rating scale motor sub-scale (UPDRSIII/MDS-UPDRSIII). We defined tremor predominant PD as a score of 2 or more on the tremor subscore with a score of 1 or less in the bradykinesia and rigidity subscores. We defined hypokinetic rigid PD as a score of 2 or more on the rigidity and bradykinesia subscores with a score of 1 or less on the tremor subscore. All other patients were considered mixed. We compared patients who had weight or height gain after DBS in the two groups and tested significance with the chi-square test. A P value less than 0.05 was considered significant. Patients with mixed phenotype were not included in the comparative analysis.

3. Results {#sec3}
==========

There were 130 patients in the dataset (70% male, mean age 63+/-9.1). Most patients were implanted in the subthalamic nucleus (STN) = 124 (95.3%). Eighty-eight patients had available weight and height data at 1-year post-DBS or longer. Mean LAF was 4.36+/-1.64 years post-DBS at the time of data analysis. The average preoperative weight was 83.3 kg (SD: 18.4), height was 172.8 cm (SD: 10.4), and BMI was 27.8 kg/M^2^ (SD: 5.5). At one year post surgery, BMI increased in 55% of the patients and the increment was higher than 1 kg/M^2^ in 35% and higher than 2 kg/M^2^ in 17%. An increase in standing height occurred in 33% of the patients at 1 year post-surgery and the increment was higher than 1 cm in 24% and higher than 2 cm in 15%. The average postoperative weight at 1-year was 84.8 kg (SD: 18.6) higher than the preoperative average by 1.5 kg. The average postoperative standing height at 1-year was 173.09 cm (SD: 9.6) higher than the preoperative average by 0.29 centimeter. The average postoperative BMI at 1-year was 28.2 kg/M^2^ (SD: 5.3) higher than the preoperative average by 0.4 kg/M^2^.

At LAF, 54% of the patients continued to have a BMI that was higher than their preoperative value but 45% of the patients experienced a decrease in their BMI as the disease progressed abolishing the overall difference in the average BMI between the preoperative and the postoperative periods of the cohort as a whole (average postoperative weight and BMI at LAF of 83.4 kg and 27.8 kg/M^2^ respectively). Twenty three patients (48%) out of the original 48 with postoperative increased weight maintained their weight gain at the LAF while the remaining patients lost weight with time. Sixteen patients (40%) out of the original 40 with postoperative stable or decreased weight at 1-year post surgery lost more weight at the LAF. Increased standing height compared to preoperative value was still seen in 23% of patients at LAF and the increment was higher than 1 cm in 19% and higher than 2 cm in 14%. However, 28% of the patients experienced reduction in their standing height at LAF bringing down the average of the entire cohort at LAF to the same value of the preoperative average (172.8 cm, SD: 9.4).

Based on clinical symptoms and UPDRSIII/MDS-UPDRSIII sub-scores, 28 patients were classified as tremor-predominant PD and 55 were classified as hpokinetic-rigid PD, while 5 patients could not be classified into either group. [Table 1](#tbl1){ref-type="table"} summarizes the demographic and clinical data of both groups. At 1-year post-DBS, 41.8% of patients with hypokinetic-rigid subtype increased in standing height compared to only 14.2% of the tremor-predominant patients (OR 4.3, 95 % CI 1.3167 to 14.1246, P = 0.015). This difference was not maintained at LAF. There was no correlation between PD clinical subtype and weight change at 1-year post DBS or at the LAF.Table 1Baseline demographics and clinical data of the tremor-predominant versus hypokinetic-rigid groups.Table 1Tremor-predominant PDHypokinetic-rigidMale %85%69%Average age64.03 years62.5 yearsAverage disease duration at surgery8.5 years11.2 yearsAverage preoperative ON UPDRSIII23.9818.09Average preoperative LEDD925.6 mg1151.2 mgDyskinesia presence %17.8%54.5%Average Preoperative weight91.7 kg79.6 kgAverage Preoperative height176.6 cm171.1 cmAverage Preoperative BMI29.3 kg/cm^2^27 kg/cm^2^

4. Discussion {#sec4}
=============

Our results suggest that the effect of weight gain after DBS on patients' BMI may be mitigated in some patients by a concomitant increase in standing height although the effect on weight remains more pronounced. Fourteen patients had an increase in both weight and height at one year post-surgery accounting for 29% of all patients who had increased BMI. This means that in a subset of PD patients postoperative increase in weight is partially offset by concomitant increase in height mitigating the net effect on BMI. There was no correlation between the rate of weight gain and the increase in height. The increase in height seems to occur more frequently in patients with hypokinetic-rigid parkinsonism which suggests that DBS may improve axial rigidity. Although several studies have shown that DBS can improve axial dystonia in camptocormic patients based on angular improvement \[[@bib6], [@bib7]\], our study strongly suggests that DBS might result in actual improvement in axial rigidity as represented by the increase in standing height 1-year post-surgery even in the absence of camptocormia (i.e: in patients with average stooping due to axial rigidity in absence of full-blown truncal dystonia). This observation is of particular importance as it suggests that the limited effect of DBS on axial symptoms \[[@bib8], [@bib9]\] might not be absolute. In addition, our study suggests that tremor resolution with DBS is unlikely a major factor in the observed weight gain after surgery since there was no difference in weight gain between tremor-predominant and hypokinetic-rigid patients. Other factors may be implicated in post-DBS weight gain like decreased dyskinesia or appetite simulation effect. These factors will require further studies in the future. BMI changes after DBS is an important topic since preoperative BMI may influence DBS outcomes as reported previously by us and other authors \[[@bib10], [@bib11]\]. As expected, the effect of DBS on weight and height was most pronounced at 1-year post surgery then it became less pronounced at the LAF due to disease progression although a subset of patients maintained their weight and height gain several years postoperatively. Weight loss in advanced PD has been frequently described and is often multifactorial with proposed contributions from dysphagia, anorexia, hypomotility of the gastrointestinal tract, depression, and increased energy expenditure secondary to tremor and dyskinesia [@bib12]. One important limitation to our study is that the height and weight changes after DBS were not compared to a non-DBS control group. Also since height measuring was done as part of routine intake rather than a structured research protocol, there is a chance that some of the smaller variations in height were technical in nature.

5. Conclusion {#sec5}
=============

In summary, our findings confirm previous reports of weight gain after DBS and highlight a novel finding of increased height in patients with hypokinetic-rigid PD which might mitigate DBS effect on BMI by virtue of increased denominator. These effects become less prominent as the disease progresses leading to weight loss and worsened posture. In addition, tremor resolution is probably not a major factor in postoperative weight gain. The effect of perioperative weight and height changes on different DBS outcomes is a potential area for future research.
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